AML Patient Case: 52-Year-Old Woman With History of Breast Cancer (Part 3)
October 18, 2021 • AML Clinical Content Hub
Part 3 – Case Discussion & Wrap-up
Gabriel N. Mannis, MD, presents the case of patient “J.A.” to fellow faculty members Brian A. Jonas, MD, PhD, FACP, and Daniel A. Pollyea, MD, MS. The virtual roundtable panel discusses unique features of the case and explores hypothetical variations of the circumstances, as well as offering insights into how the latest data from clinical trials may impact the future of treatment for patients with acute myeloid leukemia (AML).
Disclosures: Brian A. Jonas, MD, PhD, FACP Consulting Fees: AbbVie, Genentech, GlycoMimetics, Jazz, Takeda Contracted Research: 47, AbbVie, Amgen, AROG, Celgene, Daiichi-Sankyo, Forma, Genentech/Roche, GMI, Hanmi, Jazz, Pfizer, PCYC Travel Reimbursement: AbbVie Gabriel N. Mannis, MD Consulting Fees: AbbVie, Agios, BMS/Celgene, Genentech, Pfizer Contracted Research: Gilead/Forty Seven, Glycomimetics, Jazz Daniel A. Pollyea, MD, MS Consulting Fees: Celgene, Abbvie, Genentech, Novartis, Karyopharm, Syndax, BMS Other: Takeda, Syros, Kiadis, Foghorn, Aprea, Gilead, Amgen, Astellas
